TAPUR Study Overview
The primary objective of the Targeted Agent and Profiling Utilization Registry (TAPURTM) Study is to describe the anti-tumor activity and toxicity of Food and Drug Administration (FDA)-approved, targeted anti-cancer drugs prescribed for treatment of patients whose tumors have genomic alterations known to be drug targets or predicted sensitivity to a TAPUR Study drug. The TAPUR Study offers a clinical trial opportunity for patients with advanced cancer who have not responded or are no longer responding to standard treatment.
How the TAPUR Study Works
The TAPUR Study is enrolling patients at clinical sites around the country. Review the statements below to determine if your patient may be eligible for the TAPUR Study. For detailed eligibility criteria and for a list of study drugs, refer to www.clinicaltrials.gov; NCT02693535, or contact the TAPUR Study team using the “Contact Us” form below.
* Subject to cohort availability. As of June 2018, enrollment of patients with multiple myeloma and non-Hodgkin lymphoma is suspended until further notice.
The TAPUR Study is open and enrolling patients at 116 clinical sites. Most of the clinical sites are part of a larger network, and all questions and/or referrals should be directed to the primary contact at the main operations center.
Clinical Sites Interested in the TAPUR Study
Clinical sites interested in participating in the TAPUR Study are invited to complete our interested site questionnaire. Additional information regarding the timeline for site evaluation is provided on the questionnaire.
TAPUR Study News & Updates
View the latest study news, including links to press releases, information on study progress, and timely updates of interim cohort analyses and closures.